Hormonal
Tirzepatide, a dual agonist of GLP-1 and GIP receptors, achieves significant body weight and glucose control in patients with obesity and type 2 diabetes.
Tirzepatide, which activates both GLP-1 and GIP receptors, is an effective treatment for obesity and type 2 diabetes, leading to significant improvements in body weight and glucose control. It represents a newer class of therapy with promising clinical results.
Interest in GIPR agonism for the treatment of obesity and diabetes was recently propelled by the clinical success of unimolecular dual-agonists targeting the receptors for GIP and GLP-1, with reported significantly improved body weight and glucose control in patients with obesity and type II diabetes.
Why this rating
Described as 'clinical success' and 'experimental drug candidate' with 'reported significantly improved' outcomes, but specific trial data is not detailed in the text.
Source
Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes
Qiming Tan et al. · Frontiers in Endocrinology · 2022
DOI 10.3389/fendo.2022.838410
More from this paper
- Semaglutide 2.4 mg administered once weekly induces significant body weight reduction (>10% in ~69% of patients) in non-diabetic adults with obesity when used as an adjunct to lifestyle programs.Strong
- GLP-1 receptor agonists reduce the risk of major adverse cardiovascular events (MACE), death, and stroke in patients with type 2 diabetes.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →